MERS-CoV vaccine
Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
1. An immunogenic composition comprising a nucleic acid molecule selected from the group consisting of:
a) a nucleic acid molecule comprising a fragment of SEQ ID NO:1 encoding an immunogenic fragment of SEQ ID NO:2, wherein the fragment comprises a sequence having 100% identity to consecutive bases over at least 60% of the full length of SEQ ID NO:1; and
b) a nucleic acid molecule comprising a fragment of SEQ ID NO:3 encoding an immunogenic fragment of SEQ ID NO:4, wherein the fragment comprises a sequence having 100% identity to consecutive bases over at least 60% of the full length of SEQ ID NO:3.
2. The immunogenic composition of claim 1 , wherein the nucleic acid molecule comprises a fragment of SEQ ID NO:1 or SEQ ID NO:3, wherein the fragment comprises at least 90% of SEQ ID NO:1 or SEQ ID NO:3.
3. The immunogenic composition of claim 1 , further comprising:
(a) a peptide comprising an amino acid sequence having at least about 90% identity over an entire length of the amino acid sequence set forth in SEQ ID NO:2; or
(b) a peptide comprising an amino acid sequence having at least about 90% identity over an entire length of the amino acid sequence set forth in SEQ ID NO:4.
4. The immunogenic composition of claim 1 , wherein the nucleic acid molecule comprises an expression vector.
5. The immunogenic composition of claim 1 , wherein the nucleic acid molecule is incorporated into a viral particle.
6. The immunogenic composition of claim 1 , further comprising a pharmaceutically acceptable excipient.
7. The immunogenic composition of claim 1 , further comprising an adjuvant.
8. A method of inducing an immune response against a Middle East Respiratory Syndrome coronavirus (MERS-CoV) in a subject in need thereof, the method comprising administering an immunogenic composition of claim 1 to the subject.
9. The method of claim 8 , wherein administering includes at least one of electroporation and injection.
10. A method of protecting a subject in need thereof from infection with a Middle East Respiratory Syndrome coronavirus (MERS-CoV), the method comprising administering an immunogenic composition of claim 1 to the subject.
11. The method of the claim 10 , wherein administering includes at least one of electroporation and injection.
12. A method of treating a subject in need thereof against Middle East Respiratory Syndrome coronavirus (MERS-CoV), the method comprising administering an immunogenic composition of claim 1 to the subject, wherein the subject is thereby resistant to one or more MERS-CoV strains.
13. The method of claim 12 , wherein administering includes at least one of electroporation and injection.